Cyclacel Pharmaceuticals, Inc.
CYCC
$0.269
-$0.0102-3.65%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.00K | 4.00K | 29.00K | 31.00K | 16.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.00K | 4.00K | 29.00K | 31.00K | 16.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 10.00K | 4.00K | 29.00K | 31.00K | 16.00K |
| SG&A Expenses | 1.24M | 1.63M | 1.60M | 1.87M | 1.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.19M | 3.65M | 4.38M | 5.39M | 6.86M |
| Operating Income | -2.18M | -3.64M | -4.36M | -5.36M | -6.85M |
| Income Before Tax | -2.17M | -3.67M | -4.30M | -5.69M | -6.70M |
| Income Tax Expenses | -210.00K | -412.00K | -1.35M | -422.00K | -668.00K |
| Earnings from Continuing Operations | -1.96M | -3.26M | -2.95M | -5.27M | -6.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.96M | -3.26M | -2.95M | -5.27M | -6.03M |
| EBIT | -2.18M | -3.64M | -4.36M | -5.36M | -6.85M |
| EBITDA | -2.18M | -3.64M | -4.35M | -5.35M | -6.84M |
| EPS Basic | -0.91 | -1.80 | -2.27 | -6.23 | -7.22 |
| Normalized Basic EPS | -0.63 | -1.27 | -2.07 | -4.17 | -4.97 |
| EPS Diluted | -0.91 | -1.80 | -2.27 | -6.23 | -7.22 |
| Normalized Diluted EPS | -0.63 | -1.27 | -2.07 | -4.17 | -4.97 |
| Average Basic Shares Outstanding | 2.15M | 1.81M | 1.30M | 854.00K | 842.90K |
| Average Diluted Shares Outstanding | 2.15M | 1.81M | 1.30M | 854.00K | 842.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -0.95% | -0.83% |
